TrialCancer science2021

Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.

Ikuko Hirai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.